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Abstract
Using a phenome-wide association study (PheWAS) approach, we comprehensively tested genetic variants for association
with phenotypes available for 70,061 study participants in the Population Architecture using Genomics and Epidemiology
(PAGE) network. Our aim was to better characterize the genetic architecture of complex traits and identify novel pleiotropic
relationships. This PheWAS drew on five population-based studies representing four major racial/ethnic groups (European
Americans (EA), African Americans (AA), Hispanics/Mexican-Americans, and Asian/Pacific Islanders) in PAGE, each site with
measurements for multiple traits, associated laboratory measures, and intermediate biomarkers. A total of 83 single
nucleotide polymorphisms (SNPs) identified by genome-wide association studies (GWAS) were genotyped across two or
more PAGE study sites. Comprehensive tests of association, stratified by race/ethnicity, were performed, encompassing
4,706 phenotypes mapped to 105 phenotype-classes, and association results were compared across study sites. A total of
111 PheWAS results had significant associations for two or more PAGE study sites with consistent direction of effect with a
significance threshold of p,0.01 for the same racial/ethnic group, SNP, and phenotype-class. Among results identified for
SNPs previously associated with phenotypes such as lipid traits, type 2 diabetes, and body mass index, 52 replicated
previously published genotype–phenotype associations, 26 represented phenotypes closely related to previously known
genotype–phenotype associations, and 33 represented potentially novel genotype–phenotype associations with pleiotropic
effects. The majority of the potentially novel results were for single PheWAS phenotype-classes, for example, for CDKN2A/B
rs1333049 (previously associated with type 2 diabetes in EA) a PheWAS association was identified for hemoglobin levels in
AA. Of note, however, GALNT2 rs2144300 (previously associated with high-density lipoprotein cholesterol levels in EA) had
multiple potentially novel PheWAS associations, with hypertension related phenotypes in AA and with serum calcium levels
and coronary artery disease phenotypes in EA. PheWAS identifies associations for hypothesis generation and exploration of
the genetic architecture of complex traits.
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Introduction
Phenomic approaches are complementary to the more preva-
lent paradigm of genome-wide association studies (GWAS), which
have provided some information about the contribution of genetic
variation to a wide range of diseases and phenotypes [1]. While a
typical GWAS evaluates the association between the variation of
hundreds of thousands, to over a million, genotyped single
nucleotide polymorphisms (SNPs) and one or a few phenotypes,
a common limitation of GWAS is the focus on a pre-defined and
limited phenotypic domain. An alternate approach is that of
PheWAS, which utilizes all available phenotypic information and
all genetic variants in the estimation of associations between
genotype and phenotype [1]. By investigating the association
between SNPs and a diverse range of phenotypes, a broader
picture of the relationship between genetic variation and networks
of phenotypes is possible.
A challenge for PheWAS is the availability of large studies with
genotypic data that are also linked to a wide array of high quality
phenotypic measurements and traits for study. Biorepositories
linked to electronic medical records (EMR) have been an initial
resource for PheWAS, but these EMR-based studies are often
limited to phenotypes and traits commonly collected for clinical
use and may represent sets of limited racial/ethnic diversity [2,3].
While there is no U.S. national, population-based cohort [4],
several diverse, population-based studies exist with tens of
thousands of samples linked to detailed survey, laboratory, and
medical data. These large population-based studies have limita-
tions [5], but collectively [6] they offer an opportunity to perform a
PheWAS of unprecedented size and diversity.
To capitalize on the potential for collaborative discovery among
some of the large population-based studies of the U.S., the National
HumanGenomeResearch Institute (NHGRI) funded the Population
Architecture using Genomics and Epidemiology (PAGE) network.
PAGE includes eight extensively characterized, large population-
based epidemiologic studies where data were collected across multiple
racial/ethnic groups, supported by a coordinating center [7],
providing an exceptional opportunity to pursue PheWAS with a
large number of SNPs, and thousands of phenotypic measurements
including a wide range of common diseases, risk factors, intermediate
biomarkers and quantitative traits in diverse populations. Herein, we
illustrate the feasibility and utility of the PheWAS approach for large
population-based studies and demonstrate that PheWAS provides
information on, and exposes the complexity of, the relationship
between genetic variation and interrelated and independent pheno-
types. We have found PheWAS results that replicate previously
identified genotype-phenotype associations with the exact phenotype
in previous associations or closely related phenotypes, as well as a
series of novel genotype-phenotype associations. This data explora-
tion method exposes a more complete picture of the relationship
between genetic variation and phenotypic outcome. PheWAS
provides the unbiased, high throughput design achieved by GWAS
in the genome and phenotype domains simultaneously. This
approach changes the paradigm of phenotypic characterization and
allows for exploratory research in both genomics and phenomics.
Results
Data from five PAGE study sites were available for this
PheWAS: Epidemiologic Architecture for Genes Linked to
Environment (EAGLE) using data from the National Health and
Nutrition Examination Surveys (NHANES); the Multiethnic
Cohort Study (MEC); the Women’s Health Initiative (WHI);
and two studies of the Causal Variants Across the Life Course
(CALiCo) group: the Cardiovascular Health Study (CHS) and
Atherosclerosis Risk in Communities (ARIC). Text S1 provides
full information on study design, phenotype measurement, and
genotyping for each study. These studies collectively include four
major racial/ethnic groups: European Americans (EA), African
Americans (AA), Hispanics/Mexican Americans (H), and Asian/
Pacific Islanders (API). All PAGE study sites included both males
and females, except for WHI (which includes only women). Table 1
provides an overview of the sample sizes by PAGE study site as
well as the number of SNPs and phenotypes available for this
PheWAS. Sample size and the number of phenotypes varied
across studies, and the sample size for various phenotypes within
each study varied dependent on the number of individuals for
which a given phenotype was measured. The number of
phenotypes available for this PheWAS ranged within studies from
63 (MEC) to 3,363 (WHI). Study sites also had differing numbers
of genotyped SNPs, and Table S1 contains the list of all SNPs
available for two or more sites in this study, arranged by previously
associated phenotypes. The PAGE network has focused on
characterization of well-replicated variants across multiple race/
PheWAS for Detection of Pleiotropy in PAGE
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ethnicities, so each study independently genotyped a set of SNPs
with previously reported associations with phenotypes such as
body mass index, C-reactive protein, and lipid levels.
Tests of association assuming an additive genetic model were
performed independently by each PAGE study site for each SNP
and each phenotype, stratified by race/ethnicity. The last column
of Table 1 presents the total number of comprehensive associa-
tions with and without a p-value cutoff of 0.01, showing the
proportion of significant results for this many tests of association.
The total number of tests of association ranged from .20,000
(MEC) to .1 million (WHI) reflecting the variability in both the
number of phenotypes available for study as well as the number of
SNPs genotyped by each PAGE study site. As expected, the total
number of significant tests of association (p,0.01) represented a
fraction of the total number of tests performed.
Results from these tests of association were then compared
across study sites to identify overlapping significant associations, as
these results most likely represent robust findings. To facilitate
determining overlapping significant associations, similar pheno-
types that existed across more than one study were binned into 105
distinct phenotype-classes. For some phenotypes, the specific
phenotype existed across more than one PAGE study, such as for
the phenotype ‘‘Hemoglobin’’, where hemoglobin measurements
were available for ARIC, CHS, EAGLE, and WHI. Other groups
of phenotypes binned within phenotype-classes were within similar
phenotypic domains but were not represented in exact same form
across studies. Table S2 contains a list of the study level
phenotypes, the study from which the phenotype is available,
and the phenotype-class for each phenotype that overlapped with
another study.
The same or similar phenotypes may or may not have been
collected by each PAGE study. Thus, the number of studies that
were available for comparison of results across studies varied from
one phenotype-class to another phenotype-class. Table 2 presents
the number of results where at least two of five independent studies
had SNP-phenotype associations with p,0.01 for single pheno-
type-class and single race/ethnicity group, compared to the total
number of SNP-phenotype association tests performed. For
example, .8,500 tests of association for the same SNP and same
phenotype were available from two PAGE study sites whereas only
906 and 58 tests of association were available from four and five
PAGE study sites, respectively. There were 3 results where two or
more of the groups had a SNP–phenotype association p,0.01 for
a single phenotype class across 5 groups represented.
For this PAGE-wide PheWAS, tests of association were
considered significant across PAGE study sites where two or more
phenotypes in the same phenotype-class in the same racial/ethnic
group passed a significance threshold of p,0.01 with a consistent
direction of genetic effect. Based on these criteria, a total of 111
Table 1. Study Descriptions.
Maximum Sample Size3 Minimum Sample Size3
Study1 PMID2
Age
Range Sex EA AA H API EA AA H API # SNPs4 # Phenotypes5
Total # of Tests6
(# p,0.01)
ARIC [36] 45–64 M/F 11,068 4,007 NA NA 17 7 NA NA 69 612 138,207 (2,378)
CHS [37] 65–100 at
baseline
M/F 4,487 820 NA NA 151 116 NA NA 46 341 34,829 (550)
EAGLE [38] 12–95 M/F 2,628 2,107 2,071 NA 7 16 15 NA 236 327 359,508 (6,496)
MEC [39] 45–75 M/F 3,893 4,749 6,863 6,810 33 27 40 13 74 63 23,310 (212)
WHI [40] 50–79 at
baseline
F 13,334 4,274 2,023 927 14 5 7 5 94 3,363 1,123,366 (14,068)
Abbreviations: European American (EA), African American (AA), Hispanic/Mexican American (H), Asian/Pacific Islander (API).
1Data from PAGE studies available for this PheWAS include: Atherosclerosis Risk in Communities (ARIC), Cardiovascular Health Study (CHS), Epidemiologic Architecture
for Genes Linked to Environment (EAGLE), Multiethnic Cohort (MEC), and Women’s Health Initiative (WHI). PAGE study sites and study design descriptions are in Text S1.
2Pubmed ID of study description manuscript for each study.
3Maximum sample size and Minimum sample size are dependent both on who was genotyped and who had a specific phenotype measured. Not all phenotypic
measurements were available for all participants within each study.
4This is the total number of SNPs available for each study. Table S1 has the list of these SNPs for each study, genotyped across two or more studies.
5This includes the number of phenotypes transformed and untransformed, as well as categorical phenotypes divided into binary phenotypes, full description in
Materials and Methods.
6Total number of tests of association calculated for each study, in parenthesis is the total number of associations with p,0.01.
doi:10.1371/journal.pgen.1003087.t001
Author Summary
In phenome-wide association studies (PheWAS) all poten-
tial genetic variants in a dataset are systematically tested
for association with all available phenotypes and traits that
have been measured in study participants. By investigating
the relationship between genetic variation and a diversity
of phenotypes, there is the potential for uncovering novel
relationships between single nucleotide polymorphisms
(SNPs), phenotypes, and networks of interrelated pheno-
types. PheWAS also can expose pleiotropy, provide novel
mechanistic insights, and foster hypothesis generation.
This approach is complementary to genome-wide associ-
ation studies (GWAS) that test the association between
hundreds of thousands, to over a million, single nucleotide
polymorphisms and a single phenotype or limited pheno-
typic domain. The Population Architecture using Genomics
and Epidemiology (PAGE) network has measures for a wide
array of phenotypes and traits, including prevalent and
incident status for clinical conditions and risk factors, as
well as clinical parameters and intermediate biomarkers.
We performed tests of association between a series of
genome-wide association study (GWAS)–identified SNPs
and a comprehensive range of phenotypes from the PAGE
network in a high-throughput manner. We replicated a
number of previously reported associations, validating the
PheWAS approach. We also identified novel genotype–
phenotype associations possibly representing pleiotropic
effects.
PheWAS for Detection of Pleiotropy in PAGE
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PheWAS associations were identified (Table S3). Overall, among
the 111 significant PheWAS associations identified, 52 PheWAS
results replicated previously published genotype-phenotype asso-
ciations (Table S4), 26 represented phenotype-classes closely
related to previously known genotype-phenotype associations
(Table 3), and 33 represented novel genotype-phenotype associ-
ations (Table 4).
Known Associations—Validating the PheWAS Approach
Almost half of the PAGE PheWAS results (52/111; 48%)
replicated previously known genotype-phenotype associations.
These replicated results serve as positive controls and demonstrate
that the high-throughput PheWAS approach is feasible and valid.
As an example, low-density lipoprotein cholesterol (LDL-C) has
previously been associated with rs4420638 near APOE/APOC1/
C1P1/C2/C4 in European Americans [8,9]. In the PAGE
PheWAS, a significant association between the same SNP and
LDL-C phenotypes of the ‘‘LDL-C’’ phenotype-class in European
Americans as reported in the literature [8,9] was observed in two
PAGE study sites, with the same direction of effect (b) as well as a
third PAGE site with near significant results: ARIC
(p = 1.27610215, b=25.75), CHS (p= 7.89610212, b=27.06),
and WHI (p = 0.06, b=24.15). Figure 1 shows the significant
PheWAS LDL-C results, as well as other associations considered
significant for rs4420638 across PAGE study sites for other
phenotype-classes in a similar racial/ethnic group passed a
significance threshold of p,0.01 with a consistent direction of
genetic effect.
Related Associations
Approximately one-fourth of the PAGE PheWAS results (26/
111; 23%) represented SNP-phenotype associations in phenotype-
classes closely related to previously known genotype-phenotype
associations. For example, rs10757278 near CDKN2A/CDKN2B
has been robustly associated with myocardial infarction (MI)
[10,11]. In this PheWAS, rs10757278 was associated with the
‘‘Cardiac’’ phenotype-class, but also with the related phenotype-
classes of ‘‘Artery Treatment’’ and ‘‘Angina’’. Specifically,
rs10757278 was associated with phenotypes in the Artery
Treatment phenotype-class, such as ‘‘percutaneous transluminal
coronary angioplasty’’ (WHI, p = 2.8661026, b=20.17, EA), and
‘‘coronary bypass surgery’’ (CHS, p= 9.6061023, b=20.26, EA).
The SNP rs10757278 was also associated with phenotypes in the
Angina phenotype-class, such as presence or absence of angina
(WHI, p= 6.5961023, b=20.14, EA) and the phenotype ‘‘Ever
see a doctor because of chest pain?’’ (ARIC, p= 4.4461023,
b=20.31, EA). Replication of association of this SNP with
previously known phenotypes were also found with the phenotype-
class ‘‘Cardiac’’, with phenotypes such as ‘‘MI (Y/N)’’ (WHI,
p = 1.3961024, b=20.11, EA), and ‘‘MI status at baseline (Y/
N)’’ (CHS, p= 6.3561023, b=20.18, EA). Significant PheWAS
associations at p,0.01 for rs10757278 are plotted by phenotype in
Figure 2, as well as additional results at p,0.05.
Another example of PheWAS associations for phenotype-classes
closely related to known genotype-phenotype associations existed
for rs599839 near the CELSR2/PSRC1/SORT1 gene cluster. The
SNP rs599839 has been associated with serum LDL cholesterol
levels [8,12–14], and coronary artery disease [13,15]. In our
PheWAS, associations were found for the ‘‘LDL-C’’ phenotype-
class, as well the coronary artery disease related ‘‘Angina’’ and
lipid related ‘‘HDL-C’’ phenotype-classes, including specific
phenotypes such as ‘‘angina, presence or absence of’’ (WHI,
p = 2.1061024, b=0.25, EA), and ‘‘HDL-C’’ (WHI,
p = 1.2361023, b=20.04, AA). As expected, a significant
association was also identified for the LDL-C level related
phenotype ‘‘LDL-C (mg/dl)’’ (ARIC, p= 5.25610222, b=6.42
EA). Significant PheWAS associations at p,0.01 for rs599839 are
plotted by phenotype in Figure 3, as well as additional results at
p,0.05.
Potentially Novel Associations
PheWAS results were considered novel, if the significant
phenotype-class associations varied substantially from the previ-
ously reported GWAS and candidate gene studies. Approximately
one-third of the PAGE PheWAS results (33/111; 30%) represent-
ed novel genotype-phenotype-class associations. Further research
will be required to determine the further validity of these
exploratory results.
The most statistically significant of the novel phenotype-class
associations identified by this PheWAS include multiple associa-
tions involving phenotype-classes for hematologic traits in African
Americans (Figure 4). SNPs rs599839 (CELSR2/PSRC1),
rs10923931 (NOTCH2), rs2228145 (IL6R), rs2144300 (GALNT2),
rs10757278 (CDKN2A,CDKN2B), and rs7901695 (TCF7L2) were
each associated with white blood cell count phenotypes among AA
(significant p-values ranging 7.9661023 to 9.99610215). IL6R
rs2228145 was also associated with neutrophils and lymphocyte
numbers in AA with p-values ranging from 2.4461024 to
4.66610210. These SNPs were previously associated with LDL-
C, total cholesterol levels, and coronary artery disease (rs599839)
Table 2. The number of SNP–Phenotype tests of association for phenotype-classes varies by PAGE study site genotype and
phenotype overlap.
Number of PAGE study sites1 Number of Total Tests of Association2 Number of Significant Tests of Association3
2 8680 45
3 3295 42
4 906 21
5 58 3*
Total 12939 111
1Number of PAGE study sites where both the SNP and phenotype were available for a given phenotype class.
2Total number of tests of association, by number of PAGE study sites, where both the SNP and phenotype were available for a given phenotype class.
3Number of tests of association that was significant (p,0.01) for two or more PAGE study sites for a single phenotype class and SNP, taking into account matching
direction of effect when phenotypically relevant.
*Three results where two or more of the groups had a SNP–phenotype association p,0.01 for a single phenotype class across 5 groups represented. The most
replicated novel results across studies were for SNPs rs599839, rs10923931, and rs2228145 with hematologic traits.
doi:10.1371/journal.pgen.1003087.t002
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[8,12–14]; type 2 diabetes (rs10923931) [16]; C-reactive protein
(rs2228145) [17]; coronary heart disease, HDL-C and triglycerides
(rs2144300) [13]; MI (rs10757278) [11]; and type 2 diabetes
(rs7901695) in EA [18–20]. It is likely that the majority of the
significant findings for three of the SNPs on chromosome 1
[rs599839 (CELSR2/PSRC1), rs10923931 (NOTCH2), rs2228145
(IL6R)] are not truly novel given that these variants are likely in
linkage disequilibrium with the white blood cell count-associated
Duffy null allele (DARC rs2814778) [21,22] in African Americans.
Of note is GALNT2 rs2144300 (p = 3.3261026 in WHI and
7.9661023 in CHS), located outside the 90 Mb region known to
be associated with white blood cell counts in African Americans
[21] and possibly representing a novel genotype-phenotype
association for this trait. Also for chromosome 1, novel associations
were identified in African Americans at p,0.01 for the phenotype-
class ‘‘Hemoglobin’’ and ANGPTL3 rs1748195, previously associ-
ated with triglycerides in European-descent populations [13,19].
Of the remaining hematologic trait associations identified that
were not on chromosome 1, rs10757278 near CDKN2A/B on
chromosome 9 and TCF7L2 rs7901695 on chromosome 10 were
both associated with white blood cell count, neither of which were
previously reported in GWAS for this trait [21,22]. For CDKN2A/
B rs1333049, a SNP previously associated with type 2 diabetes,
coronary artery disease, and hypertension in European-descent
populations [15,23] p,0.01 associations were identified for the
phenotype-class of Hemoglobin. Finally, a novel association in
European Americans was noted between FADS1 rs174547, a SNP
previously associated with LDL-C [13,19], and the phenotype-
class of ‘‘Platelet Count’’ at p,0.01.
Aside from hematologic traits, the most significant novel
association identified in this PheWAS was identified for phenotypes
in the phenotype-class ‘‘Forced Expiratory Volume in 3 Seconds
(FEV3)’’ and GALNT2 rs2144300 in African Americans (p-values
ranging from 8.8261023 to 4.9061024). GALNT2 rs2144300,
previously associated with HDL-C in European Americans and
African Americans [13,24], has not previously been associated with
lung function or asthma quantitative traits. Interestingly, GALNT2
rs2144300 was also associated with phenotypes in the ‘‘Hyperten-
sion’’ phenotype-class among African Americans in this PheWAS
Specifically the phenotypes were ‘‘High blood pressure ever
diagnosed?’’ (ARIC, p= 1.6161023, b=0.24) and ‘‘Pills for
hypertension ever?’’ (WHI, 8.2761023, b=0.15). Indeed, GALNT2
rs2144300 displayed the most suggestion of pleiotropy among all the
SNPs tested in this study. In addition to the associations identified in
African Americans, rs2144300 was associated with phenotypes in
the phenotype-classes ‘‘Serum Calcium’’ (p-values ranging from
1.4761024 to 8.1061023) and ‘‘Artery Treatment’’, specifically the
phenotypes ‘‘Coronary artery bypass graft (CABG)’’ (WHI,
p= 2.4661023, b=0.24) and ‘‘Aortic aneurysm repair’’ (CHS,
5.4961023, b=0.57) in European Americans. Significant PheWAS
associations at p,0.01 for rs2144300 are plotted by phenotype in
Figure 5, as well as additional results at p,0.05.
The remaining significant novel PheWAS results have identified
potentially pleiotropic effects for SNPs previously associated with
lipid traits, type 2 diabetes, inflammation, myocardial infarction,
and body mass index. The lipid trait-associated SNPs were
associated with the ‘‘Menstruation’’ phenotype-class (specifically
age at menarche) in European Americans (CETP rs3764261), the
Figure 1. PheWAS associations for rs4420638 near APOC1. SNP rs4420638 has previously been associated with LDL cholesterol levels,
triglycerides, Alzheimer’s disease, coronary artery disease, and sporadic late onset Alzheimer’s. The length of the lines correspond to –log10(p-value),
and the lines are plotted clockwise starting at top for the association with the smallest p-value. Lines are labeled with the study-specific phenotype,
the PAGE study, racial/ethnic group, and direction of effect (+ or2). Red lines represent associations at p,0.01. ‘‘LN1’’ indicates the phenotype had 1
added to the variable, and then the variable was natural log transformed. The PheWAS phenotypes significantly associated with this SNP varied, with
known associations for LDL cholesterol levels, as well as the related phenotypes ‘‘Total cholesterol (mmol/l)’’ and ‘‘Dietary cholesterol (mg)’’, and
novel phenotypes such as ‘‘Baseline glucose (mg/dl)’’.
doi:10.1371/journal.pgen.1003087.g001
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‘‘Dieting’’ phenotype-class (APOB rs562338 in African Americans
and CELSR2/PSRC1/SORT1 rs599839 and rs646776 in European
Americans), ‘‘Thyroid Goiter’’ in European Americans (LIPG
rs2156552), ‘‘Artery Measurements’’ in European Americans (LDLR
rs6511720) and ‘‘Artery Treatment’’ in African Americans (PCSK9
rs11591147), ‘‘Plasma Serum Glucose Levels’’ (APOE/APOC1/
APOC4/APOC2/APOC3 rs4420638) in European Americans, and
the ‘‘Angina’’ phenotype-class in European Americans (CELSR2/
PSRC1/SORT1 rs646776). For the type 2 diabetes-associated SNPs,
the PheWAS-identified associations were observed for the pheno-
type-classes of ‘‘Dieting’’ (IGFBP2 rs4402960) in European Amer-
icans, ‘‘Artery’’ and ‘‘Ever Smoked’’ (ADAMTS9 rs4607103) in
European Americans, ‘‘Hypertension’’ (NOTCH2 rs10923931) in
African Americans, ‘‘Heart Rate’’ (LGR5 rs7961581) in European
Americans, and ‘‘Menstruation’’ (specifically age at menarche) in
European Americans (FTO rs8050136). Like type 2 diabetes-
associated ADAMTS9 rs4607103, BMI-associated NEGR1
rs2815752 was associated with the phenotype-class of ‘‘Ever
Smoked’’ in European Americans. The final two PheWAS-identified
significant associations involved nutrient based phenotype-classes:
MI-associated CDKN2A/B rs2383207 was associated with the
phenotype-classes of ‘‘Vitamin B12’’ in European Americans, and
inflammation-associated IL6 rs1800795 was associated with the
phenotype-class of ‘‘Carotene’’ in African Americans.
Discussion
The PheWAS results herein present the result of tests of
association between a large number of SNPs and an extensive
range of phenotypes and traits available within five studies of the
PAGE network. For this first PAGE PheWAS analysis we have
emphasized associations that replicated across two or more
independent PAGE studies for the same phenotype class and
same race/ethnicity. Most of the robust findings reported here
represent previously known genotype-phenotype relationships, but
a tantalizing few also represent potentially novel pleiotropic
relationships.
The 33 novel results presented here are intriguing, but it is
important to emphasize that these first-pass analyses are consid-
ered hypothesis-generating, exploratory, and require additional
scrutiny before the findings are further considered for follow-up,
unlike the directed a priori hypothesis-testing analyses within PAGE
that involve SNPs hypothesized to be associated with specific
phenotypes. Further analysis of PheWAS results will be on an
individual result basis and will include careful phenotype
harmonization for traits and outcomes that cross two or more
PAGE studies, as well as considerable investigation of the possible
effect of covariates such as age, sex, and environmental exposure(s)
on the association between genetic variation and phenotypic
outcome.
One of the many challenges for the interpretation of PheWAS
results is dissecting the genetic effect observed among correlated
phenotypes. In some cases, the relationship is likely attributable to
a common biological process with known genetic contribution
(e.g., body mass index and waist circumference). In other cases, the
networks that exist between intermediary and/or outcome related
phenotypes add complexity to interpreting association results. For
instance, genetic variation may impact the variation of a single
Figure 2. PheWAS associations for rs10757278 near CDKN2A/CDKN2B. SNP rs10757278 was previously associated with myocardial infarction
(MI). Associations are plotted clockwise starting at top for the association with the smallest p-value and the length of the line corresponds to –
log10(p-value). Lines are labeled with the study-specific phenotype, the PAGE study, racial/ethnic group, and direction of effect (+ or 2). Red lines
represent associations at p,0.01, and results with p,0.05 are also plotted in grey to show trends for additional phenotypes. ‘‘LN1’’ indicates the
phenotype had 1 added to the variable, and then the variable was natural log transformed. The PheWAS phenotypes significantly associated with this
SNP varied, from MI (known), to coronary artery disease and MI related phenotypes such as presence or absence of ‘‘percutaneous transluminal
coronary angioplasty’’, ‘‘angina’’, and ‘‘coronary bypass surgery’’.
doi:10.1371/journal.pgen.1003087.g002
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phenotype, but variation in that phenotype could then result in
changes in other downstream phenotypes indirectly. Examples of
added complexity include obesity leading to impaired immune
function [28], and metabolic syndrome where there is a spectrum
of risk factors that are all associated with increased risk of
cardiovascular disease and type 2 diabetes [25]. As a result,
significant associations between a genetic variant and many
phenotypes could represent a network or cascade of events. This is
a potential interpretation of results found for SNP rs10923931
(NOTCH2) in AA, where type 2 diabetes was the previously
reported association for this SNP and the novel result was found
for hypertension, and type 2 diabetes and hypertension are often a
co-occurrence. Further analysis of individual PheWAS results is
necessary to conclusively establish the impact of the relationship
between phenotypes on significant SNP-phenotype associations.
With the large number of phenotype-genotype associations
calculated, there will be an increase in type 1 error due to multiple
testing. A Bonferroni correction could be used within each
individual study to choose a cutoff for significance that controls for
multiple hypothesis testing. However, this would not take into
account the correlations that exist between the phenotypes in these
studies that impact the assumption of independence between tests
as well as the correlations between the genotypes.
For our first PAGE PheWAS analysis, we chose to seek
replication of results across studies and required the same direction
of effect as one approach to reduce the false discovery rate.
Significant results can still be found by chance across more than one
study. Multiple challenges arise when attempting to get a metric of
the type 1 error rate across multiple studies. First, as with individual
studies, correlations between phenotypes and previous associations
for the SNPs are still present. Also, there are varying type 1 error
rates depending on the number of studies available for seeking
replication. Quantification of how many results were found with a
p-value cutoff, and without a p-value cutoff, depending on the
number of studies where replication could be sought (2, 3, 4, or 5)
provides some information about the number of significant results
we found, in Table 2. Table 1 has the total number of results with
and without p-value cutoff for individual studies. It is important to
note that in cases where replication could be sought in more than
two studies, there were cases where the result replicated in 3 or more
studies, further increasing our confidence in the result.
A potential limitation of this study is the granularity of
phenotypes within our phenotype classes. The phenotypes within
some phenotype classes are the same or extremely similar, such as
white blood cell count measurements across studies. However, the
phenotype class ‘‘Artery Treatment’’ is broad in terms of the types
Figure 3. PheWAS associations for rs599839 near CELSR2/PSRC1. This SNP has previously published associations with serum LDL cholesterol
levels, total cholesterol, and coronary artery disease. Genotype-phenotype associations are plotted clockwise starting at top for the association with
the smallest p-value. The length of the line corresponds to –log10(p-value), the longer the line the more significant the result. The study race/
ethnicity/and phenotype for each tests of association are listed. Red lines represent associations at p,0.01, and results with p,0.05 are also plotted
in grey to show trends for additional phenotypes. ‘‘LN1’’ indicates the phenotype had 1 added to the variable, and then the variable was natural log
transformed. The PheWAS phenotypes significantly associated with this SNP varied, from LDL cholesterol levels (previously published), to lipid level-
related phenotypes such as ‘‘High cholesterol requiring pills ever’’. In the case of coronary artery disease, phenotypes with significant results that
were related to coronary artery disease included ‘‘Ever had pain/discomfort in your chest’’, and ‘‘Hospitalized for chest pain’’.
doi:10.1371/journal.pgen.1003087.g003
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of phenotypes included, such as presence/absence aortic aneurysm
repair and presence/absence of angioplasty of the coronary
arteries. For some classes, the replicated results encompass more
variation in the phenotypes captured, compared to other results.
As a result, significant associations between a genetic variant and
all phenotypes in a network may be present. PheWAS is an
exploratory and hypothesis generating exercise, thus the choice
was made to have a broader match for some groups of phenotypes
in order to allow for those phenotypes to be part of the exploration
of the data. In addition, misclassification of phenotypes when
matching is possible, and thus can limit identification of significant
associations across studies. Other potential limitations include
sample size/power, study heterogeneity, and the SNPs selected for
study. As shown in Table 1, there is much variability across
independent PAGE studies. While each PAGE study is sizeable,
individual tests of association may be underpowered depending on
the availability of the genetic variant, phenotype class, and race/
ethnicity. Tests of association that failed to reach statistical
significance may represent underpowered genotype-phenotype
relationships and will require larger epidemiologic or clinic-based
samples to identify. In regards to the potential impact of
heterogeneity, we have some cases where replication existed in
only two or three studies out of those where replication could be
sought. In some instances this may be due to power, but this also
may reflect the heterogeneity between studies, such as how various
phenotypes are measured in individual studies and variation in
mean age across the different studies. Finally, SNPs were originally
selected for this study to replicate known genotype-phenotype
associations and to generalize them to diverse populations. A
comprehensive set of genome-wide‘‘agnostic’’ SNPs may uncover
additional pleiotropic or novel genotype-phentoype relationships
not tested here.
Despite the the limitations present for this PheWAS, there are
multiple strengths within our study. We have had the opportunity
to perform a PheWAS of substantial size with an unprecedented
diversity of high quality phenotypic measurements and traits,
across multiple races/ethnicities. In addition, because of this
PheWAS was conducted across multiple independent studies, we
were able to identify the most robust genotype-phenotype
relationships across studies
Figure 4. PheWAS results for blood cell counts and hemoglobin levels. Eleven novel genotype-phenotype-class associations were identified
for white blood cell counts and hemoglobin levels collectively. The top track indicates the chromosomal location of each SNP, below that track is a
SNP/Phenotype identification track containing the SNP ID, as well as the phenotype, phenotype transformation if present (LN1= ln(1+variable)), and
the race-ethnicity for the test population (AA or EA). The next track is a ‘‘presence/absence’’ track, box presence indicates if the SNP was present for
ARIC (blue), CHS (red), WHI (orange), or EAGLE (purple). The next tracks are as follows: –log10(p-value), where the each p-value is plotted, the
direction of the triangle indicates the direction of effect (triangle pointed up is positive, triangle pointed down is negative), base of the triangle
corresponds to the location of the p-value, solid red line is positioned at p-value= 0.01; The next track is magnitude of effect (beta) dotted grey line is
positioned at the null; Next are coded allele frequencies (CAF) for each study; Final track is sample size for each test of association.
doi:10.1371/journal.pgen.1003087.g004
Figure 5. PheWAS associations for rs2144300 within GALNT2. The previously published associations for this SNP were with triglyceride and
HDL cholesterol levels. Genotype-phenotype associations are plotted clockwise starting at top for the association with the smallest p-value. The
length of the line corresponds to –log10(p-value), the longer the line the more significant the result. The study race/ethnicity/and phenotype for each
tests of association are listed. Red lines represent associations at p,0.01, and results with p,0.05 are also plotted in grey to show trends for
additional phenotypes. The novel PheWAS phenotypes significantly associated with this SNP varied, including white blood cell counts, forced vital
capacity at three seconds (FEV3), and serum calcium levels.
doi:10.1371/journal.pgen.1003087.g005
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Conclusion
This initial PheWAS within PAGE has presented challenges in
terms of generating high-throughput tests of association across large
epidemiologic studies as well as the synthesis of the resulting data and
its eventual interpretation. Even with these limitations, this PheWAS
demonstrates the utility of investigating the relationship between
genetic variation and an extensive range of phenotypes by validating
known genotype-phenotype associations as well as identifying novel
genotype-phenotype associations, revealing complex phenotypic
relationships and perhaps actual pleiotropy. The utility of this
hypothesis-generating approach will continue to improve over time
as more samples, variants, and phenotypes/traits across diverse
populations are available for study in PAGE and other genomic
resources. Larger, richer datasets coupled with methods develop-
ment promise to more fully reveal the complex nature of genetic
variation and its relationship with human diseases and traits.
Methods
Study Populations
All studies were approved by Institutional Review Boards at
their respective sites (details are given in Text S1). The Population
Architecture using Genomics and Epidemiology (PAGE) study
includes the following epidemiologic collections: Atherosclerosis
Risk in Communities (ARIC), Coronary Artery Risk in Young
Adults (CARIDA), Cardiovascular Health Study (CHS), the
Multiethnic Cohort (MEC), the National Health and Nutrition
Examination Surveys (NHANES), Strong Heart Study (SHS), and
Women’s Health Initiative (WHI). For this PheWAS, data were
available from ARIC, CHS, MEC, NHANES III, NHANES
1999–2002, and WHI (Table 1). The PAGE study design is
described in Matise et al [26] and the PAGE PheWAS study
design is described in Pendergrass et al [1].
Figure 6. Workflow for phenotype matching, to develop the 105 phenotype classes. A MySQL database was used to filter the data from
five studies for any results with p,0.01 to generate lists of the unique phenotypes for each individual PAGE study. The number of phenotypes that
passed this significance threshold for each of the four groups was 604 (ARIC), 331 (CHS), 63 (MEC), 324 (EAGLE), 1,342 (WHI). Note that during the
binning process, a smaller number of phenotypes are listed in Figure 6 than the total number of phenotypes referred to in the manuscript for the
actual associations, in the phenotype matching process we only took into account distinct phenotypes regardless of whether or not they were
transformed or untransformed or if they were categorical phenotypes binned into case/control phenotypes. Next, resulting phenotypes were then
manually matched up between ARIC, CHS, MEC, EAGLE and WHI using and knowledge about the phenotypes and the known focus of specific PAGE
study questions (such as arterial measurements including degree of arterial stenosis). In the last step, phenotypes from all studies, regardless of
significance from genotype-phenotype tests of association, were matched to the already-defined phenotype classes using the criteria described
above.
doi:10.1371/journal.pgen.1003087.g006
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SNP Selection and Genotyping
All SNPs considered for genotyping in PAGEwere candidate gene
or GWAS-identified variants for phenotypes and traits available in
the epidemiologic collections accessed by PAGE study sites. Cohorts
and surveys were genotyped using either commercially available
genotyping arrays (Affymetrix 6.0, Illumina 370CNV BeadChip),
and/or custom mid- and low-throughput assays (TaqMan, Seque-
nom, Illumina GoldenGate or BeadXpress). Quality control was
implemented at each PAGE study site independently. Study specific
genotyping details are described in Text S1.
In this PheWAS, data were available for SNPs previously
associated with HDL-C, LDL-C, and triglycerides [27], body mass
index, obesity [28], type 2 diabetes, glucose, insulin [29], and
measures of inflammation (C-reactive protein), among other
diseases/traits. A total of 83 SNPs overlapped across at least
PAGE study sites: ten were specifically selected for body mass
index traits replication, three for C-reactive protein, six for
coronary/cardiac traits, three for gout/kidney, 41 for lipids, and
20 for type 2 diabetes. Table S1 lists these SNPs, along with
references reporting phenotypic associations from the NHGRI
GWAS catalog [30] and the open access database of GWAS
results of Johnson et al. 2009 [31]. The NHGRI GWAS catalog
was most recently accessed in October, 2011. If no references were
available from either of those two sources, a PubMed search was
performed to retrieve relevant citations.
Statistical Methods
All tests of association were performed independently by each
PAGE study site using the following analysis protocol: Linear or
logistic regressions were performed for continuous or categorical
dependent variables, respectively, assuming an additive genetic
model (0, 1, or 2 copies of the coded allele). For variables with
multiple categories, binning was used to create new variables of
the form ‘‘A versus not A’’ for each category, and logistic
regression was used to model the new binary variable. Linear
regressions were repeated following a y to log (y+1) transformation
of the response variable with +1 added to all continuous
measurements before transformation to prevent variables recorded
as zero from being omitted from analysis. All analyses were
stratified by race-ethnicity.
Test of association were calculated for the number of SNPs and
phenotypes listed in Table 1. The software used to calculate the
associations for each study was as follows: ARIC (StatSoftware),
CHS (R [32]), MEC (SAS), MEC (SAS v9.2), WHI (R), EAGLE
(SAS v9.2 using the Analytic Data Research by Email (ANDRE)
portal of the CDC Research Data Center in Hyattsville, MD).
All association results from the tests of association were reported in
standardized templates designed by the PAGE coordinating center to
facilitate data sharing. All results were then imported into a relational
database (MySQL). The database was also used to match previously
reported GWAS data with the SNPs analyzed in this study.
Plotting Significant Results
The software PheWAS-View was developed for data visualiza-
tion of the PheWAS results as well as for plotting ‘‘Sun Plots’’ [33].
Synthesis-View [34,35] was also used to present results within this
manuscript. Both software packages are freely available software
for academic users: http://ritchielab.psu.edu/ritchielab/software,
Table 5. Example phenotype-classes and binned subphenotypes within phenotype-classes.
Phenotype Class Study Sub-phenotype binned within the phenotype-class
Asthma ARIC Asthma ever diagnosed?
Asthma ARIC Chest wheeze, whistle alot?
Asthma ARIC Chest wheeze, whistle, otherwise?
Asthma ARIC Age at 1st wheezing attack
Asthma ARIC Age asthma started
Asthma ARIC Age asthma stopped
Asthma ARIC Short of breath wheezing attack?
Asthma CHS Inhaled steroids for asthma
Asthma CHS Asthma confirmed by doctor
Asthma CHS Current asthma diagnosis by doctor
Asthma EAGLE Doctor ever told you had: asthma
Asthma MEC Asthma: History of Asthma, Hayfever, Skin Allergy, Food Allergy or Any Other Allergy from
Baseline Questionnaire
CRP CHS C-reactive protein, adjusted original values (mg/l)
CRP CHS C-reactive protein, original values (mg/l)
CRP EAGLE Serum C-reactive protein (mg/dL)
Hemoglobin ARIC Hemoglobin
Hemoglobin CHS hemoglobin (g/dl)
Hemoglobin EAGLE Hemoglobin (g/dL)
Hemoglobin WHI Hemoglobin (gm/dl)
Hemoglobin EAGLE Mean cell hemoglobin concentration
Hemoglobin EAGLE Mean cell hemoglobin: SI (pg)
Presented below are examples of phenotypes binned into three phenotype classes, ‘‘Asthma’’, ‘‘BMI’’, and ‘‘CRP’’. Table S2 contains the complete list of matched
phenotypes across studies within phenotype-classes, for all phenotype-classes used within this study.
doi:10.1371/journal.pgen.1003087.t005
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and can be used with a web interface at: http://visualization.
ritchielab.psu.edu/.
Matching Phenotypes
A total of 105 phenotype-classes were developed to manually
match related phenotypes across studies. To bin related pheno-
types into classes the following steps were used as visualized in
Figure 6: First, using a MySQL database, the data from EAGLE,
MEC, CHS, ARIC, and WHI were independently filtered for any
tests of association results at p,0.01, and then lists of the unique
phenotypes for each individual PAGE study were generated. The
number of phenotypes that passed this significance threshold for
each of the four groups was 604 (ARIC), 331 (CHS), 63 (MEC),
324 (EAGLE), 1,342 (WHI). Resulting phenotypes were then
manually matched up between ARIC, CHS, MEC, EAGLE and
WHI using knowledge about the phenotypes and the known focus
of specific PAGE study survey questions (such as bone fracture
questions used primarily for collecting information about osteo-
porosis). For some phenotypes, the specific phenotype existed
clearly across more than one PAGE study, such as for the
phenotype ‘‘Hemoglobin’’, where hemoglobin measurements were
present for ARIC, CHS, EAGLE, and WHI. Other groups of
phenotypes that fell within similar phenotypic domains but were
not represented in the same form across studies were also collected
into phenotype classes. One example is the phenotypes grouped
together for the phenotype class of ‘‘Allergy’’. EAGLE collected
specific quantitative data from allergy skin testing and had survey
questions about the presence of allergies in participants. ARIC and
MEC did not have skin allergy testing, but did have survey
questions about the presence of allergies. Thus these allergy
phenotypes were grouped together. Finally, phenotypes from all
studies, regardless of significance from genotype-phenotype tests of
association, were matched to the already-defined phenotype
classes using the criteria described above. A phenotype that
matched a phenotype class but was not associated with a SNP at
the significance threshold of p,0.01 for a single study would still
be included in the phenotype-class list. Using these criteria, a
second curator reviewed the resultant phenotypes and phenotype
classes for consistency and accuracy. To provide examples of the
phenotype-classes, and which subphenotypes were matched with
phenotype-classes, we show three phenotype-class examples in
Table 5, and Table S2 contains the matched phenotypes across
studies within the phenotype-classes for all phenotype-classes used
within this study.
It is important to note resources that can be used for further
investigation of the phenotypes listed in Table S2, as well as in the
results presented in this paper. The following study websites
contain additional information about all collected study informa-
tion, including how those phenotypes were collected:
N ARIC http://www.cscc.unc.edu/aric/
N CHS http://www.chs-nhlbi.org/CHSData.htm, https://
biolincc.nhlbi.nih.gov/static/studies/chs/Other_Documents.
htm
N WHI https://cleo.whi.org/data/Pages/home.aspx
N EAGLE h t t p : / / www . c d c . g o v / n c h s / n h a n e s /
nhanes_questionnaires.htm/
N MEC ht tp ://www.c r ch . o r g/mu l t i e t hn i c coho r t/
mec_questionnaires.htm
Criteria for Significance of Association
After creating phenotype-classes, significant PheWAS tests of
association for single genotype-phenotype associations across
PAGE studies were identified using a database query. Our criteria
for considering a PheWAS test of association significant included a
threshold of p,0.01 observed in two or more PAGE studies for
the same SNP, phenotype class, and race/ethnicity and consistent
direction of effect.
A total of 111 PheWAS tests of association met our criteria for
significance (Table S3). Significant results were then binned based on
class of association: known, related, and novel. In this PheWAS,
Known Associations are positive controls and represent previously
reported genotype-phenotype associations. Related Associations are
SNPs significantly associated in this PheWASwith phenotypes judged
to be closely related to phenotypes among Known Associations found
here and the literature. Novel Associations are significant PheWAS
results where 1) the association does not match a known association
and 2) the phenotype for the PheWAS association is not within a
similar phenotypic domain as the phenotype of known association.
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